Renhe Pharmacy announced that its subsidiary Jiangxi Yadu Renhe Pharmaceutical Co., Ltd. received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration regarding aluminum magnesium carbonate chewable tablets, which passed the evaluation of generic drug quality and efficacy consistency assessment. The product's indications and characteristics include being a first-line medication for the digestive system, with effects of acid resistance, bile resistance, and mucosal protection, suitable for the broad treatment of various stomach diseases. As of the announcement date, the cumulative research and development expenses invested in aluminum magnesium carbonate chewable tablets by the company are approximately RMB 5 million yuan.